COVID-19: Fujifilm form a partnership with Dr. Reddy’s /Global Response Aid: for the drug Avigan.
COVID-19:
FUJIFILM:
On July 1, we formed a tie-up with a pharmaceutical company in India for the COVID-19 therapeutic drug/Avigan.
It has announced that it has signed an agreement with India’s leading pharmaceutical company, Dr. Reddy’s /Global Response Aid.
This contract:
In regions other than China and Russia, Dr. Reddy’s, etc. will pay the price according to the sales to Fujifilm instead of having exclusive authority.
In order to popularize the new corona as a therapeutic drug, we will establish a supply network early by using the sales channels of our contractors.
KYODO
https://this.kiji.is/650959550778623073
Fujifilm partners with Dr. Reddy’s and Global Response Aid for deployment of a COVID-19 treatment drug outside of Japan
TOKYO, July 1, 2020
FUJIFILM Corporation partners with
Dr. Reddy’s Laboratories Ltd. , a global pharmaceutical company headquartered in India
and
Global Response Aid , a global provider of medical supplies and pharmaceuticals,
aimed at overseas deployment of a treatment drug for the novel coronavirus infectious disease, or COVID-19.
On June 30, a Tripartite Licensing Agreement was concluded between
- FUJIFILM Toyama Chemical Co., Ltd.,
- Dr. Reddy’s, and
- GRA,
concerning the development, manufacture and sales of Avigan® Tablets (generic name: favipiravir) (hereinafter “Avigan”), which is a potential drug for a treatment of COVID-19.
Under the Agreement, FUJIFILM Toyama Chemical
will grant Dr. Reddy’s and GRA the exclusive right to develop, manufacture*1 and sell Avigan overseas*2, and, receive a lump-sum license fee and royalties on sales.
Based on the Agreement, FUJIFILM Toyama Chemical
will provide Dr. Reddy’s and GRA an array of data on Avigan’s preclinical and clinical studies that
FUJIFILM Toyama Chemical
has accumulated thus far. Dr. Reddy’s and GRA, for their part, will make use of this data to swiftly implement clinical studies,
targeting COVID-19 patients in
- India,
- the Middle East, and
- other regions where infections have been spreading.
In addition, FUJIFILM Toyama Chemical
will grant Dr. Reddy’s right to use Avigan’s patents of formulation and manufacturing method.
Dr. Reddy’s
will herewith establish a setup for manufacturing drugs of the same quality as Avigan, and utilize GRA’s global sales network to supply the manufactured drugs swiftly and in a stable manner.
Dr. Reddy’s is a global pharmaceutical company which develops, manufactures, and sells generic drugs.
It has been expanding business not only in India but also in Europe, the US and several other markets across the world and is accelerating its global business development.
GRA, a company based in Dubai,
offers medical supplies, drugs, and medical services worldwide in cooperation with drug and medical device manufacturers.
Fujifilm [Japan]
https://www.fujifilm.com/jp/en/news/hq/5109
Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19
https://www.drreddys.com/media/904732/press-release_dr-reddys-avigan.pdf
Agility launches Dubai-based Global Response Aid in Covid-19 fight